Current, but not past, use of MHT was associated with an elevated risk of ER+ breast cancer (aOR = 2.04, 95%CI: 1.28–3.24) and ER+/PR+ breast cancer (aOR = 2.29, 1.41–3.72). The gene discussed is ESR1; the disease is breast carcinoma.